

Osteoblast proliferation and differentiation on a barrier membrane in combination with BMP2 and TGF β 1

Richard J. Miron · Nikola Saulacic · Daniel Buser ·
Tateyuki Iizuka · Anton Sculean

Received: 26 December 2011 / Accepted: 25 May 2012 / Published online: 6 June 2012
© Springer-Verlag 2012

Abstract

Objectives Bioresorbable collagen membranes are routinely utilized in guided bone regeneration to selectively direct the growth and repopulation of bone cells in areas of insufficient volume. However, the exact nature by which alveolar osteoblasts react to barrier membranes as well as the effects following the addition of growth factors to the membranes are still poorly understood. The objective of the present study was therefore to investigate the effect of a bioresorbable collagen membrane soak-loaded in growth factors bone morphogenetic protein 2 (BMP2) or transforming growth factor β 1 (TGF β 1) on osteoblast adhesion, proliferation, and differentiation.

Material and methods Prior to experimental seeding, membranes were soaked in either BMP2 or TGF β 1 at a concentration of 10 ng/ml for 5 min.

Results Human osteoblasts adhered to all soak-loaded membranes as assessed by scanning electron microscopy. Growth factors BMP2 and TGF β 1 increased osteoblast proliferation at 3 or 5 days post-seeding when compared to control

collagen membranes. Analysis of real-time PCR revealed that administration of BMP2 increased osteoblast differentiation markers such as osterix, collagen I, and osteocalcin. BMP2 also increased mineralization of primary osteoblasts as demonstrated by alizarin red staining when compared to control and TGF β 1 soak-loaded membranes.

Conclusion The combination of a collagen barrier membrane with growth factors TGF β 1 and BMP2 significantly influenced adhesion, proliferation, and differentiation of primary human osteoblasts.

Clinical relevance The described in vitro effects following the combination of collagen barrier membranes with growth factors TGF β 1 and BMP2 provide further biologic support for the clinical application of this treatment strategy in guided bone regeneration procedures.

Keywords Barrier membranes · Growth factors · Guided bone regeneration · GBR · GTR

R. J. Miron · A. Sculean (✉)
Department of Periodontology, School of
Dental Medicine, University of Bern,
Freiburgstrasse 7,
3010 Bern, Switzerland
e-mail: anton.sculean@zmk.unibe.ch

R. J. Miron · N. Saulacic · D. Buser
Department of Oral Surgery and Stomatology,
School of Dental Medicine, University of Bern,
Bern, Switzerland

N. Saulacic · T. Iizuka
Department of Cranio-Maxillofacial Surgery,
Bern University Hospital, Inselspital,
Bern, Switzerland

Introduction

In guided tissue regeneration (GTR) and guided bone regeneration (GBR), a barrier membrane is utilized to selectively direct the growth and repopulation of periodontal ligament and bone cells in periodontal and bone defects [1, 2]. Regenerative surgery involving the use of GTR has proven to be an effective method for periodontal and bone regeneration and is widely used for the treatment of periodontal and bone defects [1, 3–7]. Since its first clinical use in the early 1980s [8, 9], new innovative materials have been designed to increase the effectiveness of the barrier membranes. Such membranes should be capable of facilitating cell attachment, increasing cell proliferation, and

promoting cell migration to the surface of the underlying defect [10–13].

A variety of synthetic and natural bioresorbable barriers have been fabricated and studied both *in vitro* and *in vivo* [3–6, 14–17]. Such materials must provide biocompatibility, tissue integration, cell occlusivity, space-making ability, and clinical ease of use [18]. The first generation of barrier membranes was fabricated from nonbioresorbable expanded polytetrafluorethylen but required a second surgery to remove the barrier thus bearing the possibility of damaging the newly formed tissue and increasing patient morbidity. Chance of reinjury of the newly formed periodontal and bone tissues combined with crestal resorption of the alveolar bone and bacterial colonization were commonly reported [19, 20]. More recently, synthetic bioresorbable membranes were fabricated primarily from polylactic, polyglycolic acids, and collagen filaments fabricated in multiple cross-linking patterns and techniques, such as ultraviolet light, glutaraldehyde, diphenylphosphoryl azide, and hexamethylene diisocyanate, in order to prolong degradation of collagen filaments by enzymatic activity of infiltrating macrophages and leukocytes [21–27]. Many of the commercially available GTR membranes fabricated from porcine collagens I and III showed similar clinical results without the need of a second surgery [3, 18, 28–30] being fully resorbable 6 months post-surgery [14, 31].

A novel approach to GBR is the use of growth factors which promote the regeneration of selective tissues. Of particular relevance are the use of bone morphogenetic protein (BMP) and transforming growth factor β (TGF β); both BMPs and TGF β have been shown to increase the proliferation and differentiation of mesenchymal cells and osteoblasts *in vitro* [32–39] and improve the speed and quality of new bone formation *in vivo* [40–46]. In an attempt to further improve clinical outcomes, dental clinicians recently introduced the combination of GTR barrier membrane procedures with growth factors such as BMP2 and TGF β 1 [47–50]. However, the exact nature by which alveolar osteoblasts react to barrier membranes as well as the effects following addition of growth factors to the membranes are still poorly understood. Therefore, the aim of the present study was to investigate the effect of a bioresorbable collagen membrane soak-loaded in growth factors BMP2 or TGF β 1 on osteoblast adhesion, proliferation, and differentiation.

Methods

Membrane coating with BMP2 and TGF β 1

The GTR membranes used in this study were a 30×40-mm bioresorbable bilayer collagen membrane (Geistlich Bio-

Gide®, Wolhusen, Switzerland). It is obtained from porcine collagen under standardized and certified procedures. For *in vitro* experiments, membranes were cut under sterile conditions to fit in the bottom of 24- and 6-well culture plastic dishes. Prior to experimental seeding, membranes were soaked in either BMP2 (Part # 892143, R&D Systems, Minneapolis, USA) or TGF β 1 (Part # 891127, R&D Systems, Minneapolis, USA) at 10 ng/ml [51, 52] for 5 min to simulate clinical application. All images viewed in this study are oriented to visualize membrane sides that are intended to guide bone regeneration as opposed to epithelial tissue.


Osteoblast cell isolation and differentiation

Human bone chips were cultured according to an explant model [53] under signed informed consent approved by the ethics committee of the Canton of Berne, Switzerland as previously described [54]. Primary human alveolar osteoblasts from three donors not demonstrating any signs of periodontal disease were detached from the tissue culture plastic using trypsin solution (Invitrogen, Basel, Switzerland). Cells used for experimental seeding were from passages 4–6. During cell seeding, α -MEM medium was supplemented with 50 μ g/ml ascorbic acid and 2 mM β -glycerophosphate to promote osteoblast differentiation. Primary osteoblasts were seeded on membranes at a density of 10,000 cells in 24-well culture plates (Falcon, Franklin Lakes, NJ, USA) for cell attachment, cell proliferation, and scanning electron microscopy (SEM) experiments and 50,000 cells for alizarin red experiments. For PCR experiments, cells were seeded at 100,000 cells on membranes in six-well culture plates. For experiments lasting longer than 5 days, medium was replaced twice weekly.

Adhesion and proliferation assays

Primary osteoblasts were seeded on the growth factor soak-loaded and non-loaded bioresorbable collagen membranes in 24-well plates at a density of 10,000 cells per well. Cells were quantified using measurement of DNA at 4 and 8 h for cell adhesion and 1, 2, 3, and 5 days for cell proliferation. At desired time points, the cells were washed with PBS and lysed by ultrasonic homogenization in 400 μ l of 0.1 % (v/v) Triton X-100 (Sigma Aldrich, Basel, Switzerland). The DNA contents of the cell extracts were determined using a commercial kit including the fluorescent dye Picogreen (QuantIT, Invitrogen) under standard protocol. Fluorescent readings were performed on an Infinite 200 microplate reader (Tecan Group Ltd. Männedorf, Switzerland) at an

Fig. 1 SEM analysis of collagen barrier membrane. **a, b** Membrane surface reveals many collagen fibrils that are intertwined with one another with various diameters and directions (magnification $A=\times 50$, $B=\times 200$). **c** High-resolution SEM demonstrates collagen fibrils ranging in diameter between 1 and 5 μm (magnification $=\times 1,600$). **d** Cross-sectional view of collagen barrier membrane of approximately 300 μm (magnification $=\times 100$)



excitation wavelength of 480 nm and an emission reading of 520 nm. Experiments were performed in triplicate with three independent experiments for each condition. Data were analyzed for statistical significance using two-way analysis of variance with Bonferroni test.

Scanning electron microscopy

For SEM, bioresorbable membranes were fixed in 1 % glutaraldehyde and 1 % formaldehyde with or without osteoblasts seeded at a density of 10,000 cells per 24-well culture. Following dehydration with ethanol, samples were dried to a critical point (Type M.9202 Critical Point Dryer, Roth & Co. Hatfield, PA, USA). Next, the samples were sputtered (DCM-010, Balzers, Liechtenstein) with a 10-nm layer of gold and analyzed microscopically using a scanning electron microscope (XL30 FEG, Philips, Netherlands) to determine micro- and nanotopographies of bioresorbable membrane as well as cell shape of osteoblasts attached to membrane surfaces.

Real-time PCR

Total RNA was isolated using TRIZOL reagent and RNeasy Mini kit (QIAGEN, Basel, Switzerland) at time points 3 and 10 days for osteoblast differentiation markers. Primer and probe sequences for genes encoding alkaline phosphatase (ALP, Hs01029144_m1), runt-related transcription factor 2 (Runx2, Hs00231692_m1), collagen1 α 1 (COL1A1, Hs01028970_m1), osteocalcin (OC, Hs01587814_g1), and glyceraldehyde 3-phosphate

dehydrogenase (GAPDH, Hs03929097_g1) were purchased as pre-designed gene expression assays (Applied Biosystems, Basel, Switzerland). Real-time (RT)-PCR was performed using 20 μl final reaction volume of TaqMan[®] One-Step Master Mix kit. RNA quantification was performed using a Nanodrop 2000c with 100 ng of total RNA was used per sample well. All samples were assayed in triplicate and three independent experiments were performed. The $\Delta\Delta\text{Ct}$ method was used to calculate gene expression levels normalized to GAPDH values and calibrated to control membranes without additional growth factors at 3 days. Data were log-transformed prior to analysis by two-way ANOVA with Bonferroni test using GraphPad Software v. 4 (GraphPad Software, La Jolla, CA, USA).




Fig. 2 Attachment assay of 10^4 primary human osteoblasts seeded on control, TGF β 1 soak-loaded, or BMP2 soak-loaded barrier membranes as assessed by total dsDNA. No significant difference in cell attachment could be observed for all groups at all time points




Fig. 3 SEM analysis of primary human osteoblasts seeded on control (a), TGFβ1 soak-loaded (b), and BMP2 soak-loaded (c) collagen barrier membranes at 8 h post-seeding. Osteoblasts attach and spread

well on all surfaces demonstrating the excellent biocompatibility of collagen barrier membranes with or without growth factor incorporation

Alizarin red quantification

Alizarin red staining was performed to determine the presence of extracellular matrix mineralization after 14 days. Osteoblasts were seeded at a density of 50,000 cells per 24-well culture dish onto bioresorbable collagen membranes. After 14 days, cells were fixed in 96 % ethanol for 15 min and stained with 0.2 % alizarin red solution in water (pH 6.4) at room temperature for 1 h. Alizarin red was dissolved using a solution of 20 % methanol and 10 % acetic acid in water for 15 min. Liquid was then transferred to cuvettes and read on a spectrophotometer at a wavelength of 450 nm. After subtraction of background, absorbance values were normalized to DNA content. Data were analyzed for statistical significance using one-way analysis of variance with Tukey's test.

Results

Barrier membrane visualization

Collagen barrier membranes developed from porcine origin are viewed in Fig. 1 by SEM. Membrane sides intended to guide bone regeneration show a high composition of collagen in fibrillar form (Fig. 1a, b). High-resolution SEM demonstrates various diameter sizes of collagen fibrils ranging in size from 1 to 5 μm (Fig. 1c). The cross-sectional view of collagen barrier membranes is presented in Fig. 1d.

Adhesion of osteoblasts to barrier membranes

At 4 and 8 h post-seeding, primary human osteoblasts adhered to collagen membranes irrespective of coating with TGFβ1 or BMP2 displaying its excellent biocompatibility (Fig. 2). In 4 h, osteoblasts seeded on barrier membranes displayed near 100 % adhesion. SEM analysis of primary osteoblasts seeded on barrier membranes was visualized at 8 h post-seeding (Fig. 3). All osteoblasts attached well on all

surfaces and displayed excellent cell spreading on each surface (Fig. 3).

Osteoblast proliferation on barrier membranes

Osteoblast numbers were quantified at 1, 3, and 5 days post-seeding (Fig. 4). At 1 day, no significant difference was observed between all groups (Fig. 4). At 3 days post-seeding, barrier membranes soak-loaded with TGFβ1 and BMP2 displayed significant increases in cell numbers when compared to control non-soaked barrier membranes (Fig. 4). Similar patterns were also observed at 5 days post-seeding with barrier membranes soak-loaded with BMP2 showing the highest rate of proliferation at both 3 and 5 days post-seeding (Fig. 4).

Osteoblast differentiation on barrier membranes

Osteoblasts were assessed for Runx2, OC, COL1α1, and OSX at 3 and 14 days post-seeding. Analysis of the transcription factor Runx2 gene expression showed no significant differences in mRNA levels at 3 and 14 days for all groups (Fig. 5a). COL1α1 mRNA levels showed significantly higher values of mRNA at 3 and 14 days post-seeding





Fig. 4 Proliferation assay of 10^4 primary osteoblasts seeded on control, TGFβ1 soak-loaded, or BMP2 soak-loaded barrier membranes as assessed by total dsDNA. (Asterisk denotes significant difference, $p < 0.05$)

Fig. 5 Real-time PCR of osteoblasts seeded on control, TGF β 1 soak-loaded, and BMP2 soak-loaded barrier membranes for genes encoding **a** Runx2, **b** Col1 α 1, **c** OC, and **d** OSX. (Asterisk denotes significant difference, $p < 0.05$)



for osteoblasts seeded on barrier membranes containing either TGF β 1 or BMP2 (Fig. 5b). Up to a twofold increase in COL1 α 1 mRNA levels was observed for BMP2 soak-loaded barrier membranes. At 14 days post-seeding, a significant increase in mRNA expression of OC was observed for osteoblasts seeded on BMP2-treated barrier membranes when compared to control and TGF β 1 samples (Fig. 5c). OSX also displayed up to a threefold increase in mRNA expression in BMP2 soak-loaded membranes when compared to control and TGF β 1 samples (Fig. 5d). Alizarin red staining at 14 days demonstrated significantly increased mineralization for osteoblasts seeded on BMP2 soak-loaded barrier membranes when compared to control and TGF β 1 samples (Fig. 6).

Discussion

Over the past 20 years, the use of barrier membranes has dramatically improved clinical outcomes in patients with significant bone loss [3–6]. Furthermore, the combination of barrier membranes and different bone grafts has been shown to additionally ameliorate the results [55–57]. In the present study, the hypothesis that additional growth factors such as TGF β 1 and BMP2 would additionally improve the outcomes generated from resorbable collagen barrier membranes was tested on osteoblast adhesion, proliferation, and differentiation. Since the majority of our understanding for the TGF β superfamily comes from loss-of-function studies which result in embryonic

lethality, much of our understanding of the regulatory mechanisms of action for either growth factor is determined using in vitro studies [33]. Results from the present study would support the use of either growth factor in GTR or GBR procedures.

Previously, it has been shown that TGF β 1 enhances osteoblast proliferation and differentiation by stimulating expression of ALP, BSP, and osteonectin as determined by immunohistochemistry, RT-PCR analysis, and in vitro mineralization [58, 59]. In the present study, it was found that TGF β 1 had an effect on osteoblast proliferation. Still, only limited additional benefits were observed during differentiation of osteoblasts as assessed by real-time PCR experiments and alizarin red staining. Interestingly, it has been




Fig. 6 Normalized alizarin red staining absorbance values at 14 days post-seeding. BMP2 soak-loaded barrier membranes displayed significantly higher mineralization when compared to control and TGF β 1 soak-loaded barrier membranes. (Asterisk denotes significant difference, $p < 0.05$)

reported that primary human osteoblasts harvested from different age groups showed that TGF β 1 had a more pronounced effect on cells harvested from old patients as opposed to young and middle-aged patients [60].

The other growth factor tested in this study, BMP2, seems to be the growth factor of choice for clinical application in a variety of surgical procedures including dentistry, orthopedics, fracture healings, and spinal fusions [61–63]. In three studies comparing BMP2 and TGF β 1, BMP2 was able to stimulate osteoblast proliferation and/or differentiation such as ALP and OC in murine cell lines MC3T3-E1 and C3H10T1/2, while TGF β 1 had a less pronounced effect [37, 64, 65]. Intriguingly, neither BMP2 nor TGF β 1 had an effect on Runx2 in the current study, suggesting actions independent or downstream of this osteoblast-specific transcription factor. BMP2 induced the expression of OSX while TGF β 1 had only moderate effects (Fig. 5). Previously, it has been demonstrated that BMP2 induces OSX expression through upregulation of Dlx5 and its phosphorylation by p38 [66].

Previously, the combination of BMP2 for clinical application has been investigated both in vivo and in clinical trials [47–50]. Cochran et al. tested rhBMP-2 using a collagen sponge carrier to stimulate bone formation in defects in the canine mandible around endosseous dental implants. The addition of rhBMP-2 significantly enhanced new bone area and percentage of bone-to-implant contact after 4 and 12 weeks of healing [47]. In a subsequent study, the use of BMP2 for patients receiving rhBMP-2 loaded in an absorbable collagen sponge (ACS) in human extraction sites or in sites that required alveolar ridge augmentation demonstrated safety 2 years following surgical implantation of rhBMP-2/ACS (0.43 mg/ml) [48].

More recently, Sawyer et al. demonstrated in a rat model that the release of rhBMP2 from a collagen scaffold is a clinically applicable approach for the repair and regeneration of critically sized craniofacial bone defects [49]. However, a randomized controlled clinical trial evaluating the long-term outcome of implants placed in bone augmented with a xenogenic bone substitute material and a collagen membrane with or without the addition of rhBMP-2 demonstrated no statistically significant differences between test and control sites after 3 and 5 years posttreatment [50].

Results from previous animal and human studies combining BMPs with collagen membranes have demonstrated mixed outcomes [47–50, 67]. One question that remains unresolved is the effect/use of high doses of rhBMP2 for single application procedures. In the present in vitro study, the local use of BMP at a concentration of 10 ng/ml was able to stimulate an effect in primary human osteoblasts. Previously, lower concentrations of BMP2 combined to 3D poly(lactic-co-glycolic acid) scaffolds ranging in doses from 30 to 240 ng/mm³ were able to increase bone regeneration in a 5-mm critical sized rat calvarial defect in a dose-

dependent manner [67]. Clinically, the use of doses ranging from 4 to 8 mg has been reported, an increase of almost 1,000 times the concentration used in the present study. Since collagen barrier membranes are able to adsorb growth factor proteins, it is plausible that a lower concentration may be required. These observations further indicate the necessity to accurately administer the appropriate doses of growth factors for specific clinical procedures. The use of an animal model to test the effect of both TGF β 1 and BMP2 in combination with a collagen barrier membrane is, however, mandatory before clinical application.

In conclusion, the combination of a collagen barrier membrane with growth factors TGF β 1 and BMP2 significantly influenced adhesion, proliferation, and differentiation of primary human osteoblast. All osteoblasts attached well to membranes irrespective of additional growth factors. Both TGF β 1 and BMP2 significantly enhanced osteoblast proliferation while BMP2 additionally increased osteoblast differentiation. The combination of collagen membranes with soak-loaded growth factors may bear clinical relevance by additionally improving healing following GBR. Further in vivo studies are thus warranted to support the clinical relevance of this treatment approach.

Source of funding No external funding, apart from the support of the authors' institution, was available for this study. We kindly thank Geistlich Pharma AG (Switzerland) for providing the barrier membranes used in this study.

Conflict of interest The authors declare that they have no conflicts of interest.

References

1. Karring T, Nyman S, Gottlow J, Laurell L (1993) Development of the biological concept of guided tissue regeneration—animal and human studies. *Periodontol* 2000 1:26–35
2. Bornstein MM, Bosshardt D, Buser D (2007) Effect of two different bioabsorbable collagen membranes on guided bone regeneration: a comparative histomorphometric study in the dog mandible. *J Periodontol* 78:1943–1953
3. Cortellini P, Pini Prato G, Tonetti MS (1996) Periodontal regeneration of human intrabony defects with bioresorbable membranes. A controlled clinical trial. *J Periodontol* 67:217–223
4. Yukna CN, Yukna RA (1996) Multi-center evaluation of bioabsorbable collagen membrane for guided tissue regeneration in human class II furcations. *J Periodontol* 67:650–657
5. Wang HL, O'Neal RB, Thomas CL, Shyr Y, MacNeil RL (1994) Evaluation of an absorbable collagen membrane in treating class II furcation defects. *J Periodontol* 65:1029–1036
6. Becker W, Becker BE, Mellonig J, Caffesse RG, Warrar K, Caton JG, Reid T (1996) A prospective multi-center study evaluating periodontal regeneration for class II furcation invasions and

- intrabony defects after treatment with a bioabsorbable barrier membrane: 1-year results. *J Periodontol* 67:641–649
7. Gkraniias ND, Graziani F, Sculean A, Donos N (2012) Wound healing following regenerative procedures in furcation degree III defects: histomorphometric outcomes. *Clin Oral Invest* 16:239–249
 8. Gottlow J, Nyman S, Karring T, Lindhe J (1984) New attachment formation as the result of controlled tissue regeneration. *J Clin Periodontol* 11:494–503
 9. Nyman S, Lindhe J, Karring T, Rylander H (1982) New attachment following surgical treatment of human periodontal disease. *J Clin Periodontol* 9:290–296
 10. Kim BS, Mooney DJ (1998) Development of biocompatible synthetic extracellular matrices for tissue engineering. *Trends Biotechnol* 16:224–230
 11. Minuth WW, Sittinger M, Kloth S (1998) Tissue engineering: generation of differentiated artificial tissues for biomedical applications. *Cell Tissue Res* 291:1–11
 12. Grinnell F (1978) Cellular adhesiveness and extracellular substrate. *Int Rev Cytol* 53:65–144
 13. Machtei EE, Cho MI, Dunford R, Norderyd J, Zambon JJ, Genco RJ (1994) Clinical, microbiological, and histological factors which influence the success of regenerative periodontal therapy. *J Periodontol* 65:154–161
 14. Camelo M, Nevins ML, Schenk RK, Simion M, Rasperini G, Lynch SE, Nevins M (1998) Clinical, radiographic, and histologic evaluation of human periodontal defects treated with Bio-Oss and Bio-Gide. *Int J Periodont Restor Dent* 18:321–331
 15. Takata T, Wang HL, Miyauchi M (2001) Attachment, proliferation and differentiation of periodontal ligament cells on various guided tissue regeneration membranes. *J Periodontol Res* 36:322–327
 16. Takata T, Wang HL, Miyauchi M (2001) Migration of osteoblastic cells on various guided bone regeneration membranes. *Clin Oral Implants Res* 12:332–338
 17. Wang HL, Miyauchi M, Takata T (2002) Initial attachment of osteoblasts to various guided bone regeneration membranes: an in vitro study. *J Periodontol Res* 37:340–344
 18. Gottlow J (1993) Guided tissue regeneration using bioresorbable and non-resorbable devices: initial healing and long-term results. *J Periodontol* 64:1157–1165
 19. Selvig KA, Kersten BG, Chamberlain AD, Wikesjo UM, Nilveus RE (1992) Regenerative surgery of intrabony periodontal defects using ePTFE barrier membranes: scanning electron microscopic evaluation of retrieved membranes versus clinical healing. *J Periodontol* 63:974–978
 20. Nowzari H, Slots J (1995) Microbiologic and clinical study of polytetrafluoroethylene membranes for guided bone regeneration around implants. *Int J Oral Maxillofac Implants* 10:67–73
 21. Brunel G, Piantoni P, Elharar F, Benque E, Marin P, Zahedi S (1996) Regeneration of rat calvarial defects using a bioabsorbable membrane technique: influence of collagen cross-linking. *J Periodontol* 67:1342–1348
 22. Bunyaratavej P, Wang HL (2001) Collagen membranes: a review. *J Periodontol* 72:215–229
 23. Kodama T, Minabe M, Hori T, Watanabe Y (1989) The effect of various concentrations of collagen barrier on periodontal wound healing. *J Periodontol* 60:205–210
 24. Minabe M, Kodama T, Kogou T, Tamura T, Hori T, Watanabe Y, Miyata T (1989) Different cross-linked types of collagen implanted in rat palatal gingiva. *J Periodontol* 60:35–43
 25. Quteish D, Dolby AE (1992) The use of irradiated-crosslinked human collagen membrane in guided tissue regeneration. *J Clin Periodontol* 19:476–484
 26. Zahedi S, Legrand R, Brunel G, Albert A, Dewe W, Coumans B, Bernard JP (1998) Evaluation of a diphenylphosphorylazide-crosslinked collagen membrane for guided bone regeneration in mandibular defects in rats. *J Periodontol* 69:1238–1246
 27. Tatakis DN, Promsudthi A, Wikesjo UM (1999) Devices for periodontal regeneration. *Periodontol* 2000 19:59–73
 28. Caffesse RG, Mota LF, Quinones CR, Morrison EC (1997) Clinical comparison of resorbable and non-resorbable barriers for guided periodontal tissue regeneration. *J Clin Periodontol* 24:747–752
 29. Teparat T, Solt CW, Claman LJ, Beck FM (1998) Clinical comparison of bioabsorbable barriers with non-resorbable barriers in guided tissue regeneration in the treatment of human intrabony defects. *J Periodontol* 69:632–641
 30. Kohal RJ, Trejo PM, Wirsching C, Hurzeler MB, Caffesse RG (1999) Comparison of bioabsorbable and bioinert membranes for guided bone regeneration around non-submerged implants. An experimental study in the mongrel dog. *Clin Oral Implants Res* 10:226–237
 31. Zitzmann NU, Naef R, Scharer P (1997) Resorbable versus non-resorbable membranes in combination with Bio-Oss for guided bone regeneration. *Int J Oral Maxillofac Implants* 12:844–852
 32. Ryoo HM, Lee MH, Kim YJ (2006) Critical molecular switches involved in BMP-2-induced osteogenic differentiation of mesenchymal cells. *Gene* 366:51–57
 33. Soderberg SS, Karlsson G, Karlsson S (2009) Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling. *Ann N Y Acad Sci* 1176:55–69
 34. Aybar B, Emes Y, Atalay B, Vural P, Kaya AS, Eren SN, İşsever H, Bilir A (2008) Effects of bone morphogenetic protein on neonatal rat calvarial osteoblast-like cells: an in vitro study. *J Biomed Mater Res A* 86:560–568
 35. Bosetti M, Boccafroschi F, Leigheb M, Cannas MF (2007) Effect of different growth factors on human osteoblast activities: a possible application in bone regeneration for tissue engineering. *Biomol Eng* 24:613–618
 36. Fang H, Yang X, Chen A, Luo Y (2007) Effect of rhBMP-2 and osteogenic revulsants on proliferation and differentiation of bone marrow stromal cells in rats. *J Huazhong Univ Sci Technol Med Sci* 27:561–563
 37. Van der Zande M, Walboomers XF, Briest A, Springer M, Alava JJ, Jansen JA (2008) The effect of combined application of TGFbeta-1, BMP-2, and COLLOSS E on the development of bone marrow derived osteoblast-like cells in vitro. *J Biomed Mater Res A* 86:788–795
 38. Zheng Y, Wu G, Zhao J, Wang L, Sun P, Gu Z (2010) rhBMP2/7 heterodimer: an osteoblastogenesis inducer of not higher potency but lower effective concentration compared with rhBMP2 and rhBMP7 homodimers. *Tissue Eng Part A* 16:879–887
 39. Miron RJ, Zhang YF (2012) Osteoinduction: a review of old concepts with new standards. *J Dent Res*, in press
 40. Gautschi OP, Frey SP, Zellweger R (2007) Bone morphogenetic proteins in clinical applications. *ANZ J Surg* 77:626–631
 41. Liu Y, Wu G, de Groot K (2010) Biomimetic coatings for bone tissue engineering of critical-sized defects. *J R Soc Interf* 7(Suppl 5):S631–S647
 42. Axelrad TW, Einhorn TA (2009) Bone morphogenetic proteins in orthopaedic surgery. *Cytokine Growth Factor Rev* 20:481–488
 43. Burks MV, Nair L (2010) Long-term effects of bone morphogenetic protein-based treatments in humans. *J Long Term Eff Med Implants* 20:277–293
 44. Devescovi V, Leonardi E, Ciapetti G, Cenni E (2008) Growth factors in bone repair. *Chir Organi Mov* 92:161–168
 45. Herford AS (2009) rhBMP-2 as an option for reconstructing mandibular continuity defects. *J Oral Maxillofac Surg* 67:2679–2684
 46. Nauth A, Ristiniemi J, McKee MD, Schemitsch EH (2009) Bone morphogenetic proteins in open fractures: past, present, and future. *Injury* 40(Suppl 3):S27–S31
 47. Cochran DL, Schenk R, Buser D, Wozney JM, Jones AA (1999) Recombinant human bone morphogenetic protein-2 stimulation of

- bone formation around endosseous dental implants. *J Periodontol* 70:139–150
48. Cochran DL, Jones AA, Lilly LC, Fiorellini JP, Howell H (2000) Evaluation of recombinant human bone morphogenetic protein-2 in oral applications including the use of endosseous implants: 3-year results of a pilot study in humans. *J Periodontol* 71:1241–1257
 49. Sawyer AA, Song SJ, Susanto E, Chuan P, Lam CX, Woodruff MA, Hutmacher DW, Cool SM (2009) The stimulation of healing within a rat calvarial defect by mPCL-TCP/collagen scaffolds loaded with rhBMP-2. *Biomaterials* 30:2479–2488
 50. Jung RE, Windisch SI, Eggenschwiler AM, Thoma DS, Weber FE, Hämmerle CH (2009) A randomized-controlled clinical trial evaluating clinical and radiological outcomes after 3 and 5 years of dental implants placed in bone regenerated by means of GBR techniques with or without the addition of BMP-2. *Clin Oral Implants Res* 20:660–666
 51. Zhao L, Jiang S, Hantash BM (2010) Transforming growth factor beta1 induces osteogenic differentiation of murine bone marrow stromal cells. *Tissue Eng Part A* 16:725–733
 52. Laflamme C, Curt S, Rouabhia M (2010) Epidermal growth factor and bone morphogenetic proteins upregulate osteoblast proliferation and osteoblastic markers and inhibit bone nodule formation. *Arch Oral Biol* 55:689–701
 53. Bennett JH, Carter DH, Alavi AL, Beresford JN, Walsh S (2001) Patterns of integrin expression in a human mandibular explant model of osteoblast differentiation. *Arch Oral Biol* 46:229–238
 54. Miron RJ, Hedbom E, Ruggiero S, Bosshardt DD, Zhang Y, Mauth C, Gemperli AC, Iizuka T, Buser D, Sculean A (2011) Premature osteoblast clustering by enamel matrix proteins induces osteoblast differentiation through up-regulation of connexin 43 and N-cadherin. *PLoS One* 6:e23375
 55. Nygaard-Ostby P, Bakke V, Nesdal O, Susin C, Wikesjö UM (2011) Periodontal healing following reconstructive surgery: effect of guided tissue regeneration using a bioresorbable barrier device when combined with autogenous bone grafting. A randomized-controlled trial 10-year follow-up. *J Clin Periodontol* 37:366–373
 56. Schwarz F, Sahm N, Bieling K, Becker J (2009) Surgical regenerative treatment of peri-implantitis lesions using a nanocrystalline hydroxyapatite or a natural bone mineral in combination with a collagen membrane: a four-year clinical follow-up report. *J Clin Periodontol* 36:807–814
 57. Sculean A, Nikolidakis D, Schwarz F (2008) Regeneration of periodontal tissues: combinations of barrier membranes and grafting materials—biological foundation and preclinical evidence: a systematic review. *J Clin Periodontol* 35:106–116
 58. Lieb E, Vogel T, Milz S, Dauner M, Schulz MB (2004) Effects of transforming growth factor beta1 on bone-like tissue formation in three-dimensional cell culture. II: Osteoblastic differentiation. *Tissue Eng* 10:1414–1425
 59. Zhang H, Ahmad M, Gronowicz G (2003) Effects of transforming growth factor-beta 1 (TGF-beta1) on in vitro mineralization of human osteoblasts on implant materials. *Biomaterials* 24:2013–2020
 60. Zhang H, Aronow MS, Gronowicz GA (2005) Transforming growth factor-beta 1 (TGF-beta1) prevents the age-dependent decrease in bone formation in human osteoblast/implant cultures. *J Biomed Mater Res A* 75:98–105
 61. Treasure T (2010) The "bone-less" bone graft: the use of bone morphogenetic protein-2 in jaw reconstruction. *J Indiana Dent Assoc* 89:25–29
 62. Szpalski M, Gunzburg R (2005) Recombinant human bone morphogenetic protein-2: a novel osteoinductive alternative to autogenous bone graft? *Acta Orthop Belg* 71:133–148
 63. Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, Song F, Alt V (2010) Bone morphogenetic protein (BMP) for fracture healing in adults. *Cochrane Database Syst Rev* 6:CD006950
 64. Schindeler A, Morse A, Peacock L, Mikulec K, Yu NY, Liu R, Kijunnuayporn S, McDonald MM, Baldock PA, Ruys AJ, Little DG (2010) Rapid cell culture and pre-clinical screening of a transforming growth factor-beta (TGF-beta) inhibitor for orthopaedics. *BMC Musculoskelet Disord* 11:105
 65. Spinella-Jaegle S, Roman-Roman S, Faucheu C, Dunn FW, Kawai S, Galléa S, Stiot V, Blanchet AM, Courtois B, Baron R, Rawadi G (2001) Opposite effects of bone morphogenetic protein-2 and transforming growth factor-beta1 on osteoblast differentiation. *Bone* 29:323–330
 66. Ulsamer A, Ortuno MJ, Ruiz S, Susperregui AR, Osses N, Rosa JL, Ventura F (2008) BMP-2 induces osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. *J Biol Chem* 283:3816–3826
 67. Cowan CM, Aghaloo T, Chou YF, Walder B, Zhang X, Soo C, Ting K, Wu B (2007) MicroCT evaluation of three-dimensional mineralization in response to BMP-2 doses in vitro and in critical sized rat calvarial defects. *Tissue Eng* 13:501–512

Copyright of Clinical Oral Investigations is the property of Springer Science & Business Media B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.